Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T4032 versus Lumigan in ocular hypertension or open-angle glaucoma
ISRCTN17779071Phase 3Completed
- Sponsor
- Laboratoires Théa
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, single-blind trial of bimatoprost in ocular hypertension and Primary open-angle glaucoma (POAG) (2 arms), sponsored by Laboratoires Théa. Primary endpoint: Intraocular pressure. Started Jun 2022; status: completed.
02
Drugs
bimatoprost
03
Conditions
ocular hypertensionPrimary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on ISRCTN17779071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17779071.